Shares of Pandion Therapeutics soared more than 131 percent in trading after pharma giant Merck announced the acquisition of the autoimmune-focused company for up to $1.85 billion.
Dermavant Sciences announced positive safety and efficacy results from a planned interim analysis of the company’s PSOARING 3 safety study of tapinarof, a novel, once-daily therapeutic aryl hydrocarbon receptor modulating agent steroid-free cream.
Bristol Myers Squibb announced positive data from POETYK PSO-2, the second Phase III trial of deucravacitinib for moderate to severe plaque psoriasis, evaluated against placebo and Amgen’s Otezla (apremilast).
The U.S. Food and Drug Administration approved Aurinia Pharmaceuticals Inc.’s Lupkynis (voclosporin) in combination with a background immunosuppressive therapy regimen to treat adult patients with active lupus nephritis.
An investigational oral MK2 inhibitor from clinical-stage biopharmaceutical company Aclaris Therapeutics was safe and associated with promising reductions in inflammatory markers in a 12-week, Phase II study of patients with moderate to severe rheumatoid arthritis (RA).
After a start-of-the-year lull, activities at the U.S. Food and Drug Administration are starting to pick up, according to BioSpace.
A little more than one year after Gilead Sciences Inc. and Galapagos NV announced intentions to seek regulatory approval for Jyseleca (filgotinib) as a treatment for rheumatoid arthritis, the companies pulled the plug on that goal as well as others following a Complete Response Letter issued in August 2020.
A recent study shows that Bristol Myers Squibb’s oral tyrosine kinase 2 (TYK2) inhibitor deucravacitinib was associated with noticeable improvements in signs and symptoms of psoriatic arthritis compared with placebo.
Additional findings from Biogen’s Phase II LILAC study show the biotech company’s lupus drug candidate BIIB059 is superior to placebo for reducing joint disease activity in patients with systemic lupus erythematosus (SLE).
Bristol Myers Squibb’s experimental psoriasis drug deucravacitinib (BMS-986165) beat out Amgen’s Otezla (apremilast) in the POETYK PSO-1 Phase III clinical trial.